Investigation of the Differences in Activity between Hydroxycycloalkyl N1 Substituted Pyrazole Derivatives As Inhibitors of B-Raf Kinase by Using Docking, Molecular Dynamics, QM/MM, and Fragment-Based De Novo Design: Study of Binding Mode of Diastereomer Compounds
暂无分享,去创建一个
[1] Jae Yoon Chung,et al. QM/MM based 3D QSAR models for potent B-Raf inhibitors , 2010, J. Comput. Aided Mol. Des..
[2] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[3] Mirko Zimic,et al. Docking and quantitative structure–activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors , 2011, J. Comput. Aided Mol. Des..
[4] R. Friesner,et al. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .
[5] Yu-Quan Wei,et al. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[6] Julio Caballero,et al. Docking and quantitative structure–activity relationship studies for sulfonyl hydrazides as inhibitors of cytosolic human branched-chain amino acid aminotransferase , 2009, Molecular Diversity.
[7] Mathew J Garnett,et al. Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.
[8] D. Berger,et al. Discovery of highly potent and selective type I B-Raf kinase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[9] A. Adjei,et al. Inhibitors of Raf kinase and MEK signaling , 2007 .
[10] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[11] Stephen Hanessian,et al. A comparative docking study and the design of potentially selective MMP inhibitors , 2001, J. Comput. Aided Mol. Des..
[12] Julio Caballero,et al. Modeling of Cyclin-Dependent Kinase Inhibition by 1H-Pyrazolo[3, 4-d]Pyrimidine Derivatives Using Artificial Neural Network Ensembles , 2005, J. Chem. Inf. Model..
[13] R. Abagyan,et al. Pocketome via Comprehensive Identification and Classification of Ligand Binding Envelopes* , 2005, Molecular & Cellular Proteomics.
[14] Ilza Pajeva,et al. Molecular basis of inactive B-RAF(WT) and B-RAF(V600E) ligand inhibition, selectivity and conformational stability: an in silico study. , 2009, Molecular pharmaceutics.
[15] Ruben Abagyan,et al. ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..
[16] K. Morokuma,et al. ONIOM: A Multilayered Integrated MO + MM Method for Geometry Optimizations and Single Point Energy Predictions. A Test for Diels−Alder Reactions and Pt(P(t-Bu)3)2 + H2 Oxidative Addition , 1996 .
[17] Fernando D. González Nilo,et al. Insights into the Structural Basis of N2 and O6 Substituted Guanine Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors: Prediction of the Binding Modes and Potency of the inhibitors by Docking and ONIOM Calculations , 2009, J. Chem. Inf. Model..
[18] A. Ghose,et al. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.
[19] Anders Karlén,et al. Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering. , 2008, Journal of molecular graphics & modelling.
[20] Mike Welch,et al. Potent and selective pyrazole-based inhibitors of B-Raf kinase. , 2008, Bioorganic & medicinal chemistry letters.
[21] Julio Caballero,et al. 2D Autocorrelation, CoMFA, and CoMSIA modeling of protein tyrosine kinases' inhibition by substituted pyrido[2,3-d]pyrimidine derivatives. , 2008, Bioorganic & medicinal chemistry.
[22] Garland R. Marshall,et al. VALIDATE: A New Method for the Receptor-Based Prediction of Binding Affinities of Novel Ligands , 1996 .
[23] A. Giuliani,et al. An in silico study of the molecular basis of B-RAF activation and conformational stability , 2009, BMC Structural Biology.
[24] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[25] Jans H Alzate-Morales,et al. A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity. , 2007, Biophysical journal.
[26] Matthew Paul Gleeson,et al. QM/MM As a Tool in Fragment Based Drug Discovery. A Cross-Docking, Rescoring Study of Kinase Inhibitors , 2009, J. Chem. Inf. Model..
[27] Ian A. Watson,et al. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. , 2009, Journal of medicinal chemistry.
[28] Hieu T. Do,et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. , 2006, Cancer research.
[29] Jans H. Alzate-Morales,et al. A computational ONIOM model for the description of the H-bond interactions between NU2058 analogues and CDK2 active site , 2009 .
[30] K. Morokuma,et al. A NEW ONIOM IMPLEMENTATION IN GAUSSIAN98. PART I. THE CALCULATION OF ENERGIES, GRADIENTS, VIBRATIONAL FREQUENCIES AND ELECTRIC FIELD DERIVATIVES , 1999 .
[31] Óscar Villacañas,et al. Structural Analysis of the Inhibition of Cdk4 and Cdk6 by p16INK4a through Molecular Dynamics Simulations , 2002, Journal of biomolecular structure & dynamics.
[32] M. Santoro,et al. Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. , 2009, Biochimica et biophysica acta.
[33] Ricardo Vivas-Reyes,et al. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA. , 2008, Bioorganic & medicinal chemistry.
[34] Julio Caballero,et al. Docking and Quantitative Structure–Activity Relationship Studies for the Bisphenylbenzimidazole Family of Non‐Nucleoside Inhibitors of HIV‐1 Reverse Transcriptase , 2008, Chemical biology & drug design.
[35] Peng Xie,et al. Identification of BRAF inhibitors through in silico screening. , 2008, Journal of medicinal chemistry.
[36] Julio Caballero,et al. Computational Study of the Interactions between Guanine Derivatives and Cyclin-Dependent Kinase 2 (CDK2) by CoMFA and QM/MM , 2010, J. Chem. Inf. Model..
[37] Klaus R Liedl,et al. Molecular docking studies of natural cholinesterase-inhibiting steroidal alkaloids from Sarcococca saligna. , 2003, Journal of medicinal chemistry.
[38] Julio Caballero,et al. 2D Autocorrelation Modelling of the Inhibitory Activity of Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors , 2006, Bulletin of mathematical biology.
[39] Jans H. Alzate-Morales,et al. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.
[40] de novo design and synthesis of N-benzylanilines as new candidates for VEGFR tyrosine kinase inhibitors. , 2008, Organic & biomolecular chemistry.
[41] J. Sebolt-Leopold,et al. Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway , 2008, Clinical Cancer Research.
[42] Julio Caballero,et al. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses. , 2008, Bioorganic & medicinal chemistry.
[43] Michal Otyepka,et al. Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors , 2011, J. Comput. Aided Mol. Des..
[44] W. Bisson,et al. Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies. , 2009, Journal of medicinal chemistry.
[45] C. Pritchard,et al. Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.
[46] Julio Caballero,et al. Computational Study on the Interaction of N1 Substituted Pyrazole Derivatives with B-Raf Kinase: An Unusual Water Wire Hydrogen-Bond Network and Novel Interactions at the Entrance of the Active Site , 2010, J. Chem. Inf. Model..